Literature DB >> 3495748

Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy.

P J Whitehouse, W W Vale, R M Zweig, H S Singer, R Mayeux, M J Kuhar, D L Price, E B De Souza.   

Abstract

Dementias occurring in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy are associated with dysfunction and death of neurons in a variety of cell populations, including cholinergic, monoaminergic, and peptidergic systems. In the present investigation of these three disorders, we demonstrated decreased levels of corticotropin releasing factor (CRF)-like immunoreactivity in the frontal, temporal, and occipital poles of the neocortex. Moreover, reductions in peptidergic immunoreactivity correlated with reductions in the activity of choline acetyltransferase, the enzyme that catalyzes the formation of acetylcholine. The reduction in cortical CRF levels may be due to abnormalities of intrinsic cortical neurons or to dysfunction in neurons that contain CRF and innervate cortex.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495748     DOI: 10.1212/wnl.37.6.905

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Authors:  Hongxin Dong; Keely M Murphy; Liping Meng; Janitza Montalvo-Ortiz; Ziling Zeng; Benedict J Kolber; Shanshan Zhang; Louis J Muglia; John G Csernansky
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.

Authors:  Cheng Zhang; Ching-Chang Kuo; Setareh H Moghadam; Louise Monte; Kenner C Rice; Robert A Rissman
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 3.  Molecular biology and neurobiology of choline acetyltransferase.

Authors:  P M Salvaterra
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

4.  Effects of corticotrophin-releasing factor receptor 1 antagonists on amyloid-β and behavior in Tg2576 mice.

Authors:  Hongxin Dong; Shirlene Wang; Ziling Zeng; Fei Li; Janitza Montalvo-Ortiz; Christopher Tucker; Shahzad Akhtar; Jingshan Shi; Herbert Y Meltzer; Kenner C Rice; John G Csernansky
Journal:  Psychopharmacology (Berl)       Date:  2014-05-27       Impact factor: 4.530

Review 5.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

6.  Heterogeneity of Alzheimer's disease. An interpretive review.

Authors:  H H Fudenberg
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

7.  Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed non-matching to position tests.

Authors:  John B Hogan; Donald B Hodges; Snjezana Lelas; Paul J Gilligan; John F McElroy; Mark D Lindner
Journal:  Psychopharmacology (Berl)       Date:  2004-10-14       Impact factor: 4.530

8.  MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice.

Authors:  S Murai; H Saito; E Abe; Y Masuda; J Odashima; T Itoh
Journal:  J Neural Transm Gen Sect       Date:  1994

9.  Effect of infection with the 139H scrapie strain on the number, area and/or location of hypothalamic CRF- and VP-immunostained neurons.

Authors:  X Ye; R I Carp; Y Yu; R Kozielski; P Kozlowski
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 10.  Neuropathobiology of senile dementia and mechanism of action of nootropic drugs.

Authors:  O Benesová
Journal:  Drugs Aging       Date:  1994-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.